KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.

Jianxiang Wang, Bin Jiang, Jian Li, Ligen Liu, Xin Du, Hao Jiang, Jianda Hu, Menghe Yuan, Taishi Sakatani, Takeshi Kadokura, Masato Takeuchi, Masanori Kosako, Xiao Ma, Larisa Girshova, Jerome Tan, Sergey Bondarenko, Lily Wong Lee Lee, Archrob Khuhapinant, Elena Martynova, Nahla Hasabou

Leukemia 38(11) 2410-2418

PMID39237634
PMCIDPMC11518977
DOI10.1038/s41375-024-02382-9
发表日期2024-09-05
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

The phase 3 COMMODORE trial evaluated gilteritinib versus salvage chemotherapy (SC) in a predominantly Asian relapsed/refractory (R/R) FLT3-mutated (FLT3mut+) acute myeloid leukemia (AML) patient population. The primary endpoint was overall survival (OS); secondary endpoints included event-free survival (EFS) and complete remission (CR) rate. As of June 30, 2020 (interim analysis: 32.2 months after study initiation), 234 patients were randomized (gilteritinib, n = 116; SC, n = 118). Median OS was significantly longer with gilteritinib versus SC (9.6 vs. 5.0 months; HR 0.566 [95% CI: 0.392, 0.818]; p = 0.00211) with a median follow-up of 10.3 months. Median EFS was also significantly longer with gilteritinib (2.8 vs. 0.6 months; HR 0.551 [95% CI: 0.395, 0.769]; p = 0.00004). CR rates with gilteritinib and SC were 16.4% and 10.2%, respectively; composite CR rates were 50.0% and 20.3%, respectively. Exposure-adjusted grade ≥3 adverse event (AE) rates were lower with gilteritinib (58.38 events/patient-year [E/PY]) versus SC (168.30 E/PY). Common AEs with gilteritinib were anemia (77.9%) and thrombocytopenia (45.1%). Gilteritinib plasma concentration peaked ~4 h postdose; ~3-fold accumulation occurred with multiple dosing. The COMMODORE trial demonstrated that gilteritinib significantly improved OS and EFS in predominantly Asian patients, validating the outcomes of gilteritinib from the ADMIRAL trial in R/R FLT3mut+ AML.

KM 提取结果

2 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 2

Fig. 2. Overall survival by treatment group (intention-to-treat population) and subgroup analysis of overall survival. A Kaplan–Meier curve of overall survival (primary endpoint). The intention-to-treat population includes all randomized patients. The predetermined two-sided significance level was 0.00454 based on the number of observed overall survival events. B Subgroup analyses of overall survival. Preselected high-intensity therapy included FLAG or MEC; preselected low-intensity chemotherapy consisted of LoDAC. CI confidence interval, CRc composite complete remission, ECOG Eastern Cooperative Oncology Group, FLAG fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor, FLT3 FMS-like tyrosine kinase 3, HR hazard ratio, HSCT hematopoietic stem cell transplantation, IRT interactive response technology, ITD internal tandem duplication, LoDAC low-dose cytarabine, MEC mitoxantrone, etoposide, and intermediate-dose cytarabine, NE not estimable, SC salvage chemotherapy, TKD tyrosine kinase domain.

A

Overall Survival

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Overall Survival

Fig. 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Fig. 3

Fig. 3. Event-free survival by treatment group (intention-to-treat population). Kaplan–Meier curve of event-free survival (a key secondary endpoint). The predetermined two-sided significance level was 0.04011. CI confidence interval, HR hazard ratio.

Event-Free_Survival

Event-Free Survival

Fig. 3 · Panel Event-Free_Survival

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Event-Free_Survival 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. Treatment disposition, CONSORT diagram. Reasons for exclusion prior to randomization were negative FLT3 mutation status, unclear relapsed/refractory status, other inclusion criteria not met, patient withdrawal, other exclusion criteria met, investigator decision, medical records for hospitalization not available, death, and economic reasons. *Indicates patients on high-dose chemotherapy who completed one cycle of treatment with a composite complete remission and were taken off of treatment or completed two cycles of treatment. FLAG fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor, FLT3 FMS-like tyrosine kinase 3, MEC mitoxantrone, etoposide, and intermediate-dose cytarabine.
非 KM Figure